Reporter brief
Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)
What happened
Trial registry update: WITHDRAWN. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No efficacy findings are reported, so we cannot assess whether fisetin affected pain, function, or any biomarkers.
- The trial design and rationale are described but outcomes are not, making it impossible to determine if the study was completed or what it found.
- Even with results, a 3-month trial in a chronic progressive disease would not establish long-term clinical benefit or whether senolytic effects translate to meaningful symptom or disease modification.
Study design and sample
Rct; Human.
Patients with mild to moderate knee osteoarthritis
- Design
- Rct
- Sample
- 60
- Journal
- Austin V Stone
- Published
- Jul 29, 2022
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.